[Translation] An evaluation in subjects with chronic obstructive pulmonary disease (COPD) and chronic bronchitis on the basis of maintenance triple therapy
A 52-week, randomized, double-blind, placebo-controlled, parallel-group study of the efficacy and safety of adding two doses of CHF6001 DPI
于治疗52周后评价在维持三联疗法(ICS、LABA、LAMA)基础上添加两种剂量的CHF6001与维持三联疗法(即安慰剂组)相比降低中重度加重发生率的有效性
[Translation] After 52 weeks of treatment, the effectiveness of adding two doses of CHF6001 on top of maintenance triple therapy (ICS, LABA, LAMA) in reducing the incidence of moderate to severe exacerbations compared with maintenance triple therapy (i.e. placebo group) was evaluated